

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Hepalink

SHENZHEN HEPALINK PHARMACEUTICAL GROUP CO., LTD.

(深圳市海普瑞藥業集團股份有限公司)

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 9989)

VOLUNTARY ANNOUNCEMENT

“INHIXA” OBTAINS APPROVAL FROM SFDA

This announcement is made by Shenzhen Hepalink Pharmaceutical Group Co., Ltd. (the “**Company**”, together with its subsidiaries referred to as the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors of the Company (the “**Board**”) is pleased to announce that Techdow Europe AB, Sweden, a wholly-owned subsidiary of the Company, has received the registration certificates from the Saudi Food and Drug Authority (“**SFDA**”) for Inhixa, one of the Group’s leading drugs of enoxaparin sodium injection.

DETAILS OF THE DRUG

(I) Drug brand: Inhixa

(II) Indications: Prophylaxis of venous thromboembolic disease (prophylaxis of venous thrombosis), especially thrombosis related to orthopedics or general surgery; treatment of developed deep vein embolism with or without pulmonary embolism, or pulmonary embolism with light clinical syndromes, excluding pulmonary embolism requiring surgeries or thrombolytic therapies; treatment of unstable angina and non-Q-wave myocardial infarction in combination with aspirin; and used in hemodialysis and extracorporeal circulation to prevent thrombosis.

(III) Dosage form: Solution for injection

(IV) Strength: 20mg/0.2mL, 40mg/0.4mL, 60mg/0.6mL, 80mg/0.8mL, 100mg/1.0mL, 120mg/0.8mL and 150mg/1.0mL

(V) Registration Category: Prescription drug

BENEFITS AND IMPACTS TO THE COMPANY

Currently, Inhixa, Neoparin and Prolongin, the three enoxaparin sodium injection brands of the Group, have been approved in a total of 36 countries and sold in 21 countries. Meanwhile, the Group also can supply enoxaparin sodium injection to its customers in 15 other countries. The Board believes that those good feedbacks of sales and safety data in overseas markets over the past three years has enabled the Group to obtain more market share, and the Board expects that this registration approval will further accelerate the global layout advancement of the Company's finished dose pharmaceutical business.

Announcement is hereby given.

By order of the Board
Shenzhen Hepalink Pharmaceutical Group Co., Ltd
Li Li
Chairman

Shenzhen, PRC
November 4, 2020

As at the date of this announcement, the executive directors of the Company are Mr. Li Li, Ms. Li Tan, Mr. Shan Yu and Mr. Sun Xuan; the non-executive director of the Company is Mr. Bu Haihua; and the independent non-executive directors of the Company are Dr. Lu Chuan, Mr. Chen Junfa and Mr. Wang Zhaohui.